Intergrating CELMoDs with other therapies in myeloma
The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that
Meetings / Conferences
EHA 2026
Multiple Myeloma
Roundtable Discussions
Focus on CELMoDs
Video Interviews
Meetings / Conferences
ASCO 2026
Myeloproliferative Neoplasms
Primary Myelofibrosis
Video Interviews
Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974
Trending now
Meetings / Conferences
EHA 2026
Multiple Myeloma
Roundtable Discussions
Focus on CELMoDs
Video Interviews
Survivorship details from the SUCCESOR-2 trial
Dr. Banerjee reviewed the BCMA-sparing clinical efficacy data from the trial and discussed the results, which showed that MeziKd significantly extended progression-free survival
Meetings / Conferences
EHA 2026
Myeloproliferative Neoplasms
Primary Myelofibrosis
Dr. Naseema Gangat discusses initial data from RALLY-MF trial
In this interview from the 2026 European Hematology Association Congress, Naseema Gangat, MBBS, a professor of medicine at the Mayo Clinic in Rochester,
Lymphoma
Indolent B-Cell Lymphomas
EC grants marketing authorization to epcoritamab combo in second-line FL
The European Commission has granted marketing authorization to epcoritamab (TEPKINLY® ) in combination with rituximab and lenalidomide (R2) for the treatment of relapsed or
Meetings / Conferences
EHA 2026
EHA 2026: Nipocalimab shows promise in rare anemia
Warm autoimmune hemolytic anemia is a rare disease with no current approved therapy. In the trial, the investigators reported that nipocalimab had durable
Trending now
Meetings / Conferences
EHA 2026
Multiple Myeloma
Roundtable Discussions
Focus on CELMoDs
Video Interviews
What is the patient quality of life on the SUCCESOR-2 trial?
To ensure long-term clinical efficacy and treatment compliance, avoiding severe off-target side effects is vital to maintaining patient well-being, Prof. Weisel stressed. "We
Myeloproliferative Neoplasms
Polycythemia Vera
News
FDA approves ropeginterferon alfa-2b-njft pen for polycythemia vera
The US Food and Drug Administration has approved and launched a new prefilled pen device for ropeginterferon alfa-2b-njft (BESREMi Pen) for adult patients
Leukemia
Acute Lymphoblastic Leukemia
News
FDA approves allogeneic regulatory T cell-based immunotherapy for hematologic malignancies
The therapeutic indication covers patients undergoing matched donor hematopoietic stem cell transplantation (HSCT) alongside a myeloablative preparative regimen to facilitate immunologic reconstitution and
Meetings / Conferences
EHA 2026
Multiple Myeloma
Roundtable Discussions
Focus on CELMoDs
Video Interviews
What is the phase 3 SUCCESSOR-2 trial?
Dr. Dimopoulos reviews the clinical efficacy of adding the novel cereblon E3 ligase modulator (CELMoD), mezigdomide, to carfilzomib and dexamethasone (MeziKd) for patients